AbCellera Q3 net loss widens to $51.1M as expenses rise; revenue flat at $6.5M

AbCellera Biologics Inc.

2024-Q3 EPS reported -$0.44 revenue$23,783,000

Revenue $6.5M, flat QoQ and YoY; net loss $51.1M ($0.17/share) vs $28.6M ($0.10/share) in Q3 2023.
R&D expenses rose to $41.0M from $37.9M; G&A expenses increased to $19.1M from $14.4M.
Cumulative partner programs with downstreams reached 95 (up 13% YoY); molecules in clinic grew to 14 from 10.
Expanded Lilly collaboration into immunology, cardiovascular, neuroscience; completed Vancouver HQ consolidation.
Total liquidity over $875M ($670M cash + $205M government funding).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.